United States

People: MyoKardia Inc (MYOK.OQ)

MYOK.OQ on NASDAQ Stock Exchange Global Select Market

13 Dec 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Lee, June 

Dr. June Lee, M.D. is Chief Operating Officer, Chief Development Officer of the Company. Prior to joining the Company and since April 2011, Dr. Lee, served on the faculty of the University of California, San Francisco (“UCSF”), where she was director of the Catalyst program at the Clinical and Translational Science Institute and a professor in the School of Medicine, and was responsible for overall strategy and operations for enabling and supporting translational research at the university. Catalyst is an internal UCSF accelerator for therapeutics, devices, diagnostics, and digital health technologies. Prior to UCSF, Dr. Lee was a disease area lead, early clinical development, at Genentech, Inc. from 2006 to 2011, where she was responsible for all strategy and activities as well as management of staff, budget, and resource allocation in the early clinical development group in multiple therapeutic areas. Dr. Lee served as a medical director in the clinical development group at Genentech, Inc. from 2004 to 2006, where she was responsible for clinical activities for licensed product of the company. Dr. Lee holds a B.A. in chemistry from Johns Hopkins University and an M.D. from the University of California, Davis.

Basic Compensation

Total Annual Compensation, USD 402,917
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD 183,000
All Other, USD 1,164,430
Fiscal Year Total, USD 1,750,350

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Mark Perry


Tassos Gianakakos


Taylor Harris


June Lee


Joseph Lambing


Robert McDowell

As Of  30 Dec 2017